Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients Managed by Preemptive Therapy

Cytomegalovirus quantification: Where to next in optimising patient management?

(2011) Claire Atkinson et al.   JOURNAL OF CLINICAL VIROLOGY

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

(2011) Paul D Griffiths et al.   LANCET

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients

(2010) A. Humar et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients

(2010) Tomáš Reischig et al.   ANTIVIRAL THERAPY

International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation

(2010) Camille N. Kotton et al.   TRANSPLANTATION

Functional Impairment of Cytomegalovirus Specific CD8 T Cells Predicts High-Level Replication After Renal Transplantation

(2008) F. M. Mattes et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Polyfunctional Cytomegalovirus-Specific CD4+ and pp65 CD8+ T Cells Protect Against High-Level Replication After Liver Transplantation

(2008) G. Nebbia et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Programmed Death–1 Expression in Liver Transplant Recipients as a Prognostic Indicator of Cytomegalovirus Disease

(2007) Corinna La Rosa et al.   JOURNAL OF INFECTIOUS DISEASES